ReviewClinical pharmacokinetics2012
Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.
Review in Clinical pharmacokinetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Intraperitoneal chemotherapy for gastric cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Trial
- Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Evolving therapeutics in colorectal cancer peritoneal metastases.Cancer metastasis reviews · 2026Review
- Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer.Annals of surgical oncology · 2025Article
- Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives.Cancers · 2025Review
- Advancements in Hydrogel-Based Therapies for Ovarian Cancer: A Review.Cell biochemistry and biophysics · 2025Review
- Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer.Scientific reports · 2025Article
- Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.Molecular therapy. Oncology · 2024Article
- Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases.Molecular cancer · 2023Article
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.International journal of molecular sciences · 2022Review
- Modulation ofMolecular therapy oncolytics · 2022Article
- AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression.Biological procedures online · 2022Article
- Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study.Journal of gastrointestinal oncology · 2021Article
- Review
- Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.The journal of pathology. Clinical research · 2021Article
- Semiconducting polymer nanoparticles for photothermal ablation of colorectal cancer organoids.Scientific reports · 2021Article
- Advances in the surgical management of gastric and gastroesophageal junction cancer.Translational gastroenterology and hepatology · 2021Review
- Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review.Drug delivery · 2020Review
- CRS + HIPEC combined with IP + IV chemotherapy for gastric signet-ring cell carcinoma: Case report of long-term survival.Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal carcinomatosis remains a significant cause of morbidity and is a marker of poor prognosis in a range of malignancies, including those of the gastrointestinal and gynaecological tracts. In these cases, regional therapy has been explored as a treatment strategy to take advantage of the prolonged confinement of such tumours within the peritoneal cavity and the steep dose-response relationship for most cytotoxic agents. The pharmacokinetic rationale is based on exploiting the peritoneal-plasma barrier, which slows the rate of drug clearance from the peritoneal to systemic compartments and creates a concentration differential in favour of the peritoneal cavity. This allows higher drug concentrations, and thus increased cytotoxicity, to be achieved at the site of a tumour within the peritoneal cavity. There is pharmacodynamic evidence from a number of clinical trials to support the translation of these pharmacokinetic advantages of intraperitoneal chemotherapy into clinical benefit. However, its clinical application remains controversial because of concerns regarding intraperitoneal drug distribution, technical challenges and toxicity associated with regional drug delivery and the clinical relevance of the studies undertaken. The purpose of this review is to summarize the pharmacokinetic rationale of intraperitoneal drug delivery, review the pharmacodynamic studies performed in ovarian, colorectal and gastric cancers, and outline the future directions and challenges in the clinical application of this mode of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.